Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell talked with Proactive’s Stephen Gunnion about the company’s progress in developing next-generation treatments for diabetes and other cardio metabolic diseases, with a particular focus on its lead insulin candidate AT278 and its oral peptide delivery platform. Howell explained that Arecor is advancing AT278, an ultra-concentrated, ultra-rapid-acting insulin designed for use in automated insulin delivery (AID) systems. The company is targeting a significant unmet need among patients requiring intensive insulin therapy, particularly those who struggle with current pump limitations. She noted: “AT278 is the only insulin that meets this profile… and of course, we’ve shown superiority against those best-in-class insulins.” The company has made strong progress over the past year, including a co-development partnership with Sequel Med Tech to support a planned Phase 2 clinical trial in the US. Arecor also reported a positive FDA Type C ...